Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Up 5.30%
As of Monday, June 08, Filana Therapeutics, Inc.’s FLNA share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Commentary & Analysis
Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Down 5.21%
As of Wednesday, June 03, Filana Therapeutics, Inc.’s FLNA share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Up 7.02%
As of Wednesday, May 27, Filana Therapeutics, Inc.’s FLNA share price has surged by 7.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Up 10.66%
As of Tuesday, May 26, Filana Therapeutics, Inc.’s FLNA share price has surged by 10.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Down 5.24%
As of Friday, May 15, Filana Therapeutics, Inc.’s FLNA share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $48.8 | $579.1 | 16% |
|
| Shares Out (Mil) | 48.3 | 43.0 | 47% |
|
| Institutional Ownership | 93.2% | 84.3% | 63% |
|
| Float (Mil) | 47.3 | 46.8 | 46% |
|
| Beta | -0.74 | 0.62 | 1% |
|
| Avg Daily Volume (000s) | 322 | 285 | 52% |
|
| Price Change (52-week) |
(53.2%) | 63.8% | 14% |
|
| Growth | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (70.6%) | (1.4%) | 4% |
|
| EPS (5yr) | (50.6%) | 14.9% | 3 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.6%) | (14.9%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($11) | 13% |
|
| EPS (TTM) | ($1.613) | ($0.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($30) | ($6) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $522 | 2% |
|
| Valuation | FLNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.73 | 14% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (62.5%) | (24.6%) | 9% |
|
| ROE | (79.6%) | (19.7%) | 11% |
|
| Liabilities to Assets | 37.1% | 35.5% | 28% |
|
| F-Score | 1 | 3 | 1% |
|
Filana Therapeutics, Inc. did not pass any screens on 7/31/2026.
